MannKind Corp Completes Asset Acquisition

TL;DR

MNKD just bought stuff and took on debt, details to follow.

AI Summary

MannKind Corporation (MNKD) announced on October 7, 2025, the completion of an acquisition of assets. The company also entered into a material definitive agreement and created a direct financial obligation. Specific details regarding the acquired assets, the terms of the agreement, and the nature of the financial obligation were not fully disclosed in this initial filing.

Why It Matters

This filing indicates significant corporate activity for MannKind, including an acquisition and new financial obligations, which could impact its future operations and financial standing.

Risk Assessment

Risk Level: medium — The filing indicates material definitive agreements and financial obligations, suggesting significant business changes that carry inherent risks.

Key Players & Entities

• MannKind Corporation (company) — Registrant
• MNKD (company) — Ticker Symbol
• October 7, 2025 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 000-50865 (filing_id) — Commission File Number
• 13-3607736 (tax_id) — IRS Employer Identification No.
• 1 Casper Street Danbury, Connecticut 06810 (address) — Principal Executive Offices
• (818) 661-5000 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share MNKD The Nasdaq Stock Mar
• $0.0001 — s of scPharma's common stock, par value $0.0001 per share (the " scPharma Shares "), at
• $5.35 — Shares "), at a price per share of (i) $5.35 in cash (the " Cash Amount "), without
• $1.00 — ayments of up to an aggregate amount of $1.00 per CVR in cash, without interest, subj
• $0.75 — ch milestone, " Milestone 1 ") with (a) $0.75 per CVR if Milestone 1 is achieved by S
• $0.50 — is achieved by September 30, 2026, (b) $0.50 per CVR if Milestone 1 is achieved by D
• $0.25 — s achieved by December 31, 2026 and (c) $0.25 per CVR if Milestone 1 is achieved by J
• $110.0 million — Milestone Outside Dates ") of at least $110.0 million of worldwide net sales of all Injection
• $120.0 million — ) $0.25 per CVR upon the achievement of $120.0 million of worldwide net sales in such period a
• $0.10 — et sales in such period and (b) between $0.10 and $0.25 per CVR if, as of December 31
• $120.0 m — period were between $110.0 million and $120.0 million, which payment will be calculated
• $110 million — iling worldwide net sales are less than $110 million during this period. With respect to ea
• $296.5 million — r at the Closing Date was approximately $296.5 million (the " Acquisition Price "), which was
• $82.6 million — s defined below) totaling approximately $82.6 million. The foregoing summary of the Offer,
• $175.0 million — Lenders agreed to provide an additional $175.0 million incremental delayed draw term loan sole

Filing Documents

• d63266d8k.htm (8-K) — 52KB
• d63266dex101.htm (EX-10.1) — 122KB
• 0001193125-25-236064.txt ( ) — 325KB
• mnkd-20251007.xsd (EX-101.SCH) — 3KB
• mnkd-20251007_lab.xml (EX-101.LAB) — 17KB
• mnkd-20251007_pre.xml (EX-101.PRE) — 11KB
• d63266d8k_htm.xml (XML) — 3KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (a) Financial Statements of Business Acquired The financial statements required by this Item 9.01(a) will be filed by amendment to this Current Report on Form 8-K not later than 71 calendar days after the date on which this Current Report on Form 8-K is required to be filed. (b) Pro Forma Financial Information The unaudited pro forma condensed combined financial information of the Company as of and for the six months ended June 30, 2025 and the year ended December 31, 2024 required by this Item 9.01(b) will be filed by amendment to this Current Report on Form 8-K not later than 71 calendar days after the date on which this Current Report on Form 8-K is required to be filed. (d) Exhibits. Exhibit No. Description 2.1*# Agreement and Plan of Merger, dated August 24, 2025, by and among MannKind Corporation, Seacoast Merger Sub, Inc. and scPharmaceuticals Inc. (incorporated by reference to Exhibit 2.1 to MannKind Corporation's Current Report on Form 8-K (File No. 000-50865), filed with the SEC on August 25, 2025). 10.1** Contingent Value Rights Agreement, dated as of October 7, 2025, by and between MannKind Corporation and Broadridge Corporate Issuer Solutions, LLC. 10.2* Amendment No.1 to the Loan Agreement, dated August 24, 2025, among MannKind Corporation, certain subsidiaries of MannKind Corporation, Wilmington Trust, National Association, Blackstone Alternative Credit Advisors LP and the lenders from time to time party thereto (incorporated by reference to Exhibit 10.2 to MannKind Corporation's Current Report on Form 8-K (file No. 000-50865), filed with the SEC on August 25, 2025). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Previously filed. ** Filed herewith. # Certain annexes, exhibits and schedules have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant hereby undertakes to furnish supplemental copies of any of the omitted annex

View Full Filing

View this 8-K filing on SEC EDGAR